# A Phase I Study of GT300 in Healthy Subjects

> **NCT04963855** · PHASE1 · UNKNOWN · sponsor: **Generian Pharmaceuticals, Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Lewy Body Disease

## Interventions

- **DRUG:** GT300
- **DRUG:** Microcrystalline cellulose

## Key facts

- **NCT ID:** NCT04963855
- **Lead sponsor:** Generian Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-23
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2021-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04963855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04963855, "A Phase I Study of GT300 in Healthy Subjects". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT04963855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*